Immediate antiviral therapy appears to restrict resting CD4 + cell HIV-1 infection without accelerating the decay of latent infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 24, 2012, Pages 9523-9528

  Archin, Nancie M ^a   Vaidya, Naveen K ^b,c   Kuruc, JoAnn D ^a   Liberty, Abigail L ^a   Wiegand, Ann ^d   Kearney, Mary F ^d   Cohen, Myron S ^a   Coffin, John M ^e   Bosch, Ronald J ^f   Gay, Cynthia L ^a   Eron, Joseph J ^a   Margolis, David M ^a   Perelson, Alan S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV latency; Viral kinetics

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DENSITY; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LATENT VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84862189831     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120248109     Document Type: Article

References (41)

1. Blankson JN, Persaud D, Siliciano RF (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53:557-593. (Pubitemid 34177896)
2. Rong L, Perelson AS (2009) Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Comput Biol 5:e1000533.
3. Dai J, et al. (2009) Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol 83:4528-4537.
4. Chomont N, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900.
5. Kim H, Perelson AS (2006) Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLOS Comput Biol 2:e135.
6. Rong L, Perelson AS (2009) Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 260:308-331.
7. Gay C, et al. (2011) Cross-sectional detection of acute HIV infection: Timing of transmission, inflammation and antiretroviral therapy. PLoS ONE 6:e19617.
8. Archin NM, et al. (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22:1131-1135.
9. Perelson AS, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191. (Pubitemid 27209434)
10. Little SJ, Perrin L (2000) Management of acute and early HIV-1 infection. AIDS Rev 2:136-143. (Pubitemid 33121184)
11. Zaunders J, Carr A, McNally L, Penny R, Cooper DA (1995) Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 9:561-566.
12. Lynn HS (2001) Maximum likelihood inference for left-censored HIV RNA data. Stat Med 20:33-45.
13. Ribeiro RM, et al. (2010) Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 84:6096-6102.
14. Stafford MA, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203:285-301.
15. Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6:82-85. (Pubitemid 30048531)
16. Zhang L, et al. (1999) Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340:1605-1613. (Pubitemid 29249429)
17. Louie M, et al. (2003) Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 187:896-900. (Pubitemid 36337901)
18. Finzi D, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517. (Pubitemid 29220209)
19. Siliciano JD, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-728. (Pubitemid 36749221)
20. Bofill M, et al. (1992) Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 88:243-252.
21. CASCADE Collaboration (2003) Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 34:76-83.
22. Reichert T, et al. (1991) Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 60:190-208.
23. Clark SJ, et al. (1991) High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 324:954-960.
24. Daar ES, Moudgil T, Meyer RD, Ho DD (1991) Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324:961-964.
25. Mellors JW, et al. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170. (Pubitemid 26001148)
26. Piatak M, Jr., et al. (1993) High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
27. Cossarizza A, et al. (1995) Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. J Infect Dis 172:105-112.
28. Chun TW, et al. (1998) Early establishment of a pool of latently infected, resting CD4 (+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 95:8869-8873.
29. Noë A, Plum J, Verhofstede C (2005) The latent HIV-1 reservoir in patients undergoing HAART: An archive of pre-HAART drug resistance. J Antimicrob Chemother 55:410-412.
30. Maldarelli F, et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3:e46.
31. Anderson JA, et al. (2011) Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol 85:5220-5223.
32. Bailey JR, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80:6441-6457. (Pubitemid 43927447)
33. Palmer S, et al. (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41:4531-4536. (Pubitemid 37259753)
34. Chun TW, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: Implications for eradication of virus. J Infect Dis 195:1762-1764.
35. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. (Pubitemid 26097216)
36. Chun TW, et al. (1995) In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med 1:1284-1290.
37. Strain MC, et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 100:4819-4824. (Pubitemid 36457812)
38. Chun TW, et al. (2010) Rebound of plasma viremia following cessation of anti-retroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication. AIDS 24:2803-2808.
39. Palmer S, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879-3884. (Pubitemid 351723493)
40. Archin NM, et al. (2010) Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 5:e9390.
41. Lehrman G, et al. (2005) Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 366:549-555. (Pubitemid 41140329)